Graft Polymer (UK) - Research Agreement

Solvonis Therapeutics

15/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241015:nRSO1363Ia&default-theme=true

RNS Number : 1363I  Graft Polymer (UK) PLC  15 October 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

15 October 2024

Graft Polymer (UK) Plc

(the "Company")

 

Research agreement with the University of Nottingham

 

Graft Polymer (UK) Plc (LON: GPL) (the "Company"), an innovative biotechnology
company co-developing therapeutics for mental health disorders, announces that
its partner, Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF) ("Awakn"),
has entered a research agreement with the University of Nottingham. The
research will be conducted in vivo and will evaluate the potential of the
Company and Awakn's  aminoindane  new chemical entity ("NCE") co-lead series
to enhance social cognition and pro-social behaviors, a critical step in
developing a new class of medicines for treating trauma-related disorders such
as Post-Traumatic Stress Disorder ("PTSD").

 

The research will be led by Dr. Madeleine King, Assistant Professor in the
Faculty of Medicine & Health Sciences at the University of Nottingham,
which is recognised globally for its cutting-edge neuroscience research. Dr.
King brings over 20 years of experience in behavioral neuroscience, focusing
on psychiatric disorder research. The research will employ the Social
Transmission of Food Preferences ("STFP") test in rodent models and is
expected to run over two months, with results due by the end of 2024.

 

This in vivo research represents a significant step in the Company's NCE
programme, which is being developed under a collaboration agreement with
Awakn. The programme is focused on developing next-generation therapeutics for
mental health disorders, including PTSD, a condition affecting over 13 million
adults in the U.S. and 20 million across the U.S., UK, and Europe.

 

Anthony Tennyson, CEO of Graft Polymer, commented: "This is a significant step
forward in our joint programme with Awakn. The in vivo testing at the
University of Nottingham will be pivotal in assessing the therapeutic
potential of our novel aminoindane compounds, bringing us closer to addressing
the unmet needs in trauma-related mental health disorders."

 

Dr Madeline King, from the School of Life Sciences at the University of
Nottingham said: "I'm delighted that Awakn Life Sciences have chosen to
collaborate with the University of Nottingham.  I'm excited to be involved in
this research, which has real potential to improve patient health."

 

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk

 

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on
developing intellectual property relating to the treatment of mental health
and substance use disorders, and the co-development of therapeutics for mental
health disorders.  Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on trauma-related
mental health disorders, such as PTSD, which affects approximately 13 million
adults in the U.S. and 20 million in US, UK, and key EU  markets.

 

For more information, please visit www.graftpolymer.co.uk
(http://www.graftpolymer.co.uk) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESBRBDGSBBDGSS